## 단원 6
### COPD의 일반적인 진료

55. Agusti A, MacNee W, Donaldson G, et al; COPD Assessment Test Advisory Board. COPD Assessment Test (CAT): a new tool for assessing the impact of COPD in daily life. Eur Respir J 2209;34:1102-1107.
56. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
57. The National Institute for Health and Clinical Excellence (NICE). Chronic obstructive pulmonary disease. NICE clinical guideline 2010. Available from: http://guidance.nice.org.uk/CG101.
58. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 Suppl 1:1-232.
59. Korean Academy of Tuberculosis and Respiratory Diseases. The Guideline for Diagnosis and Management of COPD 2005.
60. Korea Centers for Disease Control and Prevention. The Fifth Korean National Health and Nutrition Examination Survey: KNHANES V-1.
61. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
62. Vestbo J, Hurd SS, Agusti AG, et al; Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
63. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
64. Rennard SI, Tashkin DP, Cell BR. Bronchodilator treatment in COPD: the first-line role of indacaterol. COPD 2010;7:432-441.
65. The National Institute for Health and Clinical Excellence (NICE). Chronic obstructive pulmonary disease (update). NICE clinical guideline 2010. Available from: http://guidance.nice.org.uk/CG101.
66. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/.
67. Decramer M, Celli B, Kesten S, et al; UPLIFT investigators. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:976-985.
68. Han MK, Agusti A, Celli BR, et al. From a phenotypic approach to an algorithmic approach in COPD. Chest 2010;137:1119-1126.
69. Celli BR, Vestbo J, Wedzicha JA. Update on the new GOLD guidelines for COPD. N Engl J Med 2010;362:2325-2326.
70. Jones PW, Agusti A, Celli BR, et al. COPD management: what new guidelines mean for daily practice. Lancet Respir Med 2013;1:645-654.
71. Price D, Small M, Levy ML, et al. COPD in the UK: a new approach to the diagnosis and management of COPD in primary care. Prim Care Respir J 2013;22:127-135.
72. Jones PW, Rabe KF. The COPD assessment test (CAT) and COPD-specific quality of life questionnaire (CRQ-R). Eur Respir J 2011;37:227-228.
73. Wouters EF, Vestbo J, Decramer M, et al. The Lancet respiratory medicine 2013: the 2013 GOLD strategy: a new approach to the diagnosis and management of COPD. Lancet Respir Med 2013;1:e1-e2.
74. Vestbo J, Hurd SS, Agusti AG, et al. The 2013 GOLD strategy: a new approach to the diagnosis and management of COPD. Am J Respir Crit Care Med 2013;187:347-365.
75. Hurst JR, Vestbo J, Anthonisen NR, et al. The Lancet respiratory medicine 2013: long-term clinical and economic benefits of regular tiotropium use in patients with moderate to severe COPD: a retrospective cohort study. Lancet Respir Med 2013;1:e3-e4.

<PAGE>78